Syngene

From Verify.Wiki
Jump to: navigation, search

Syngene International is one of the leading India-based contract research organisations, offering a suite of integrated, end-to-end discovery, development and manufacturing services for novel molecular entities across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. [1]

QuickUpload1085 20170610142344.png
http://www.syngeneintl.com
Type Public / Private
Founded 2000
Headquarters Bangalore, Karnataka
Number of employees 1,001-5,000


About

Incorporated in 1993 as a subsidiary of Biocon Limited, Syngene is a leading custom research and manufacturing organization, which supports R&D programs from lead generation to clinical supplies. Our multi-disciplinary skills in integrated drug discovery and development include capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development along with Clinical development services.

Our highly experienced scientific and project management teams ensure:

  • Timely execution of projects
  • Cost effectiveness and quality of the projects
  • Confidentiality and protection of intellectual property

Syngene has state-of-the-art research facilities certified with ISO 9001:2008, ISO 14001:2004, and OHSAS 18001:2007. Our animal facilities are GLP certified by the Indian authorities and AAALAC accredited. Over the last 20 years, we have successfully offered these services to more than 290 clients including start-up companies, large pharma/ biotech, agrochemical, chemical, nutrition and animal health companies in the USA, Europe and Asia Pacific including Japan.

Syngene has a strong corporate governance framework with a focus on client satisfaction, quality, safety, ethics and integrity. Our ability to deliver significant value to our customers by leveraging our scientific skills, global mind set and India’s cost competiveness differentiates us as one of the most preferred partners.

Specialties

  • Phase I-IV clinical Trials
  • BA/BE & PK/PD studies
  • Diabetology
  • Oncology
  • Rheumatology
  • Infectious diseases
  • Gastroenterology
  • Nephrology
  • Cardiology
  • Neuropsychiatry
  • Immunology

Top 5 Recent Tweets

DateAuthorComment
October 13, 2020AddyArora3In the #Nifty stocks I would say the same for #nestle #reliance #HUL #TCS #Dabur ( high PE)

&

in non-index space… https://t.co/FeIF8JCXOn
October 28, 2020keshav_sudheer@darshanvmehta1 Torrent, sanofi, syngene, biocon and now reddy.. all flat results. Is pharma party over?
October 27, 2020unseenvalue#Syngene disclosed new #biopharma CDMO relationships in their recent presentation. Operating leverage time bomb is… https://t.co/uy83wX60DK
October 28, 2020krishnakhanna#ICMCBO Alert Sell #SYNGENE CMP: 545.95 SL: 573.3728 #NimblrTA, for live alerts use https://t.co/vbjRp6Lpst #Live… https://t.co/qrgvDlJa25
October 28, 2020DeepakKatyal9@rdkriplani N even syngene, jubiliant etc u booked partially?


Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines

References

https://www.linkedin.com/company-beta/220238/

http://www.syngeneintl.com/about-syngene/overview
  1. https://www.linkedin.com/company-beta/219718/

Verification history